SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

• Status: Recruiting
• Trial end date: 2025-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multicenter, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT combined with programmed death 1 (PD-1) antibody and chemotherapy in nasopharyngeal carcinoma patients with oligometastasis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Collaborators: Chongqing University Cancer Hospital; First People's Hospital of Foshan; Jiangxi Provincial Cancer Hospital; Shenzhen People's Hospital; The First Affiliated Hospital of Xiamen University
• Treatments: Gemcitabine

Criteria

Inclusion Criteria:

• Diagnosed as metastatic NPC with no more than 3 metastatic lesions;

• Histopathological diagnosis of NPC;

• ECOG 0-1 point;

• Has not received prior systemic treatment, such as radiotherapy, chemotherapy, immunotherapy or biotherapy;

• No contraindications to immunotherapy and chemoradiotherapy;

• Every metastatic lesions could receive SBRT safely;

• Subject must have a measurable target lesion based on RECIST v1.1;

• Adequate marrow function: WBC count ≥ 3×10E9/L, NE count ≥ 1.5×10E9/L, HGB ≥ 90g/L, PLT count ≥ 100×10E9/L;

• Adequate liver function: ALT/AST ≤ 2.5×ULN, TBIL ≤ 2.0×ULN;

• Adequate renal function: BUN/CRE ≤ 1.5×ULN or endogenous creatinine clearance ≥ 60ml/min (Cockcroft-Gault formula);

• Take effective contraceptions during and three months after treatment;

• Patients must be informed of the investigational nature of this study and give written informed consent.

Exclusion Criteria:

• Allergic to monoclonal antibodies, any PD-1 antibody components, gemcitabine and cisplatin;

• Unexplained fever > 38.5 ℃, except for tumor fever;

• Have active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy);

• Have a known history of human immunodeficiency virus (HIV), active Hepatitis B (HBV-DNA ≥10E3copiers/ml) or hepatitis C virus (HCV) antibody positive;

• Have previously treated with PD-1 antibody or other immunotherapy for PD-1/PD-L1 pathway;

• Have New York Heart Association (NYHA) class 3 or 4, unstable angina, myocardial -infarction within 1 year, or clinically meaningful arrhythmia that requires treatment; Have known allergy to large molecule protein products or any compound of study therapy;

• Pregnant or breastfeeding;

• Prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical cancer, and papillary thyroid carcinoma;

• Have received a live vaccine within 30 days of planned start of study therapy Has psychiatric drug or substance abuse disorders that would interfere with cooperation with the requirements of the trial;

• Any other condition, including mental illness or domestic/social factors, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interferes with the interpretation of the results.